Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease
eNeurologicalSci · 2020-06 · 19 · 100239
DOI: 10.1016/j.ensci.2020.100239 ↗Kurz gefasst
Fachartikel in der Zeitschrift eNeurologicalSci, 2020-06. Verfasst von Shoko Kakinuma und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Uehara Memorial Foundation, NOVARTIS Foundation (Japan) for the Promotion of Science, Kyushu University.
Abstract (Originalsprache)
BACKGROUND: Dopamine replacement therapy is an established treatment for motor symptoms of Parkinson's disease, but its long-term use is often limited by the eventual development of motor complications, including levodopa-induced dyskinesia. Genetic background, particularly polymorphisms of dopamine metabolism genes, may affect the occurrence of dyskinesia in Parkinson's disease patients. METHODS: We investigated polymorphisms of dopamine metabolism genes, including catechol-O-methyltransferase, monoamine oxidase B, dopamine beta-hydroxylasedopamine, dopamine receptors D1, D2, and D3, and dopamine transporter, in 110 patients with Parkinson's disease. Cox proportional hazards regression was used to detect associations between genotypes and levodopa-induced dyskinesia. RESULTS: Monoamine oxidase B rs1799836 was the only polymorphism correlated with risk of dyskinesia. Patients with an AG or GG genotype were more likely to have dyskinesia than those with an AA genotype (adjusted hazard ratio, 3.41; 95% confidence interval, 1.28-9.10). Also, Kaplan-Meier curves demonstrated that patients with an AG or GG genotype developed dyskinesia earlier than those with an AA genotype (log-rank test, p = .004). CONCLUSIONS: In Parkinson's disease patients, the monoamine oxidase B rs1799836 G allele is associated with a greater likelihood of developing dyskinesia than the A allele, possibly due to its association with lower monoamine oxidase B activity in the brain. Thus, detection of monoamine oxidase B polymorphisms may be useful for determining the optimal dosing of antiparkinson medications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Diagnosis, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.
- Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.
- Department of Medical Technology and Sciences, International University of Health and Welfare, 2-4-16 Momochihama Sawara-ku, Fukuoka City, Fukuoka 814-0001, Japan.
- Division of Laboratory Medicine, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.
- Clinical Proteomics Research Center, Chiba University Hospital, 1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan.
Förderung
- Uehara Memorial Foundation
- NOVARTIS Foundation (Japan) for the Promotion of Science
- Kyushu University
- Takeda Science Foundation
- Naito Foundation
- GlaxoSmithKline Japan
Zitieren
APA
Kakinuma, S., Beppu, M., Sawai, S., Nakayama, A., Hirano, S., Yamanaka, Y., Yamamoto, T., Masafumi, C., Aisihaer, X., Aersilan, A., Gao, Y., Sato, K., Sakae, I., Ishige, T., Nishimura, M., Matsushita, K., Satoh, M., Nomura, F., Kuwabara, S., & Tanaka, T. (2020). Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease. eNeurologicalSci, 19, 100239. https://doi.org/10.1016/j.ensci.2020.100239
Vancouver
Kakinuma S, Beppu M, Sawai S, Nakayama A, Hirano S, Yamanaka Y, et al. Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease. eNeurologicalSci. 2020;19:100239. doi:10.1016/j.ensci.2020.100239
BibTeX
@article{Kakinuma2020,
author = {Kakinuma, Shoko and Beppu, Minako and Sawai, Setsu and Nakayama, Akitoshi and Hirano, Shigeki and Yamanaka, Yoshitaka and Yamamoto, Tatsuya and Masafumi, Chigusa and Aisihaer, Xiamuxiya and Aersilan, Alimasi and Gao, Yue and Sato, Kenichi and Sakae, Itoga and Ishige, Takayuki and Nishimura, Motoi and Matsushita, Kazuyuki and Satoh, Mamoru and Nomura, Fumio and Kuwabara, Satoshi and Tanaka, Tomoaki},
title = {Monoamine oxidase B rs1799836 G allele polymorphism is a risk factor for early development of levodopa-induced dyskinesia in Parkinson's disease},
journal = {eNeurologicalSci},
year = {2020},
volume = {19},
pages = {100239},
doi = {10.1016/j.ensci.2020.100239}
}
EUVIMED